贝达药业：拟5000万元投资知兴制药 布局高端吸入制剂领域

Core Viewpoint - The company, Betta Pharmaceuticals (300558), has completed the equity transfer with Huayuan Group, acquiring a 20% stake in Hangzhou Zhixing Pharmaceutical Co., Ltd. for 50 million yuan, indicating a strategic investment in the high-end inhalation formulation sector [1] Group 1: Company Overview - Betta Pharmaceuticals has acquired a 20% stake in Hangzhou Zhixing Pharmaceutical, which specializes in the development of high-end inhalation formulations [1] - The registered capital of Zhixing Pharmaceutical is 2 million yuan, and the investment reflects Betta's commitment to expanding its portfolio in the respiratory therapy market [1] Group 2: Product Pipeline - Zhixing Pharmaceutical has a robust product pipeline with three products in development targeting asthma and COPD, including: - Budesonide and Formoterol inhalation powder - Fluticasone Propionate inhalation suspension - Budesonide inhalation suspension - All three products have completed bioequivalence (BE) trials, with the Fluticasone Propionate inhalation suspension nearing market application [1]